Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation

Lung Transplant Rejection Clinical Trial

Official title:

A Danish, Single Centre, Double-blind, Randomized Study Evaluating Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy to Reduce Primary Graft Dysfunction After Lung Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04714801
• Other study ID #: ASC Lungtransplantation
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2020
• Est. completion date: November 30, 2024

Study information

• Verified date: July 2021
• Source: Rigshospitalet, Denmark
• Contact: Jens Kastrup, MD Professor
• Phone: +4535452819
• Email: jens.kastrup[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate safety of treatment with allogeneic adipose tissue-derived mesenchymal stromal cells (ASCs) in patients undergoing lung transplantation, to evaluate whether the treatment can reduce host immunological reaction towards the graft, and to reduce the ischemic reperfusion-injury after transplantation.

Description:

The emerging field of stem cell therapy holds promise of treating a variety of diseases. Especially the mesenchymal stromal cells from bone marrow (BMSCs) or adipose tissue (ASCs) have proven their potential for regenerative therapy in patients with ischemic heart disease. Both of these cell types have putative immunomodulatory properties, as they have demonstrated to actively suppress the immune system and hereby evade recognition.

This knowledge will be transferred into studies in the ischemic reperfusion-injury/primary lung graft dysfunction in lung transplantation, and in suppressing the initial host immunological response towards the transplanted lung where a high degree of immunological and inflammatory activity is involved.

We will conduct a clinical trial in which patients receiving lung transplantation will be randomized to either placebo or treatment with allogeneic MSCs from adipose tissue. The aim is to assess the impact of MSCs on primary graft dysfunction.

The perspective is that this new information can be of pivotal importance and potentially be a paradigm shift for the clinical problems seen in the first period after lung transplantation and reduce the long-term graft rejection and dysfunction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: November 30, 2024
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or female lung recipients 18-70 years of age undergoing primary double (including size reduction) lung transplantation.

• Patient willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 3 months.

Exclusion Criteria:

• Recipients of multi-organ transplant, and or previously transplanted with any solid organ, including previous lung transplantation.

• Patients scheduled for single lung transplantation.

• Patients in need of acute transplantation e.g. patients on urgent call for transplantation and patients on respirator or on extra corporal membrane oxygenation (ECMO) treatment at time of transplantation.

• Patients that based on crossmatch prior to transplantation have need for additional immunosuppressive treatment

• Donor lung cold ischemic time > 12 hours.

• Patients with platelet count < 50,000/mm3 at the evaluation before transplantation.

• Patients who are unlikely to comply with the study requirements.

• Patient unable to participate in the study for the full study period

• Patients with any past (within the past 3-5 years) or present malignancy (other than excised basal cell carcinoma).

• Females capable of becoming pregnant must have a negative pregnancy test prior to transplantation. After inclusion, they must use contraceptives for 2 months following the given stem cell treatment. The pill, spiral, depot injection of progesterone, sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe contraceptives.

Related Conditions & MeSH terms

• Lung Transplant Rejection

Intervention

Drug:
• adipose derived mesenchymal stromal cells
Intravenous infusion of cells
• Saline
Intravenous infusion of saline

Locations

Country	Name	City	State
Denmark	2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary graft dysfunction (PDG)	Difference in presence or not presence of Primary graft dysfunction (PGD) after transplantation in ASC treated patients compared to controls.; Primary graft dysfunction is defined, according to the International Society for Heart and Lung Transplantation (ISHLT), as presence of both pulmonary infiltrates and hypoxemia occurring within the first 72 hours after transplantation	3 days after treatment
Secondary	Kidney glomerular Filtration Rate	Difference in estimated Glomerular Filtration Rate (eGFR)/1,73 m2. Normal > 60 ml/min	12 weeks after treatment
Secondary	Inflammatory markers	Differences in C-reactive protein. Normal value < 10mg/ml	through the 12 weeks